Prognosis Markers for Monitoring HTLV-1 Neurologic Disease
- 1 April 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Clinical Practice
- Vol. 11 (2), 134-140
- https://doi.org/10.1212/cpj.0000000000000866
Abstract
Background Human T-cell lymphotropic virus type 1 (HTLV-1) infection is associated not only with some severe manifestations, such as HTLV-1-associated myelopathy (HAM) and ATLL, but also with other, less severe conditions. Some studies have reported neurologic manifestations that did not meet all the criteria for the diagnosis of HAM in individuals infected with HTLV-1; these conditions may later progress to HAM or constitute an intermediate clinical form, between asymptomatic HTLV-1 carriers and those with full myelopathy. This study evaluated the prognostic value and looked for a possible association of those parameters with the intermediate syndrome (IS) status and HAM status. Methods Proviral load (PVL), spontaneous lymphoproliferation, interferon (IFN)-γ spontaneous production was quantified in samples of asymptomatic and HAM patients, as well as patients with IS. Results The critical age range was 50–60 years for IS outcome and more of 60 years for HAM outcome, with an increased risk of 2.5-fold for IS and 6.8-fold for HAM. IFN-γ was increased in patients with IS compared with asymptomatic carriers (ACs) (p = 0.007) and in patients with HAM compared with ACs (p = 0.03). Lymphoproliferation was increased in patients with HAM vs ACs (p = 0.0001) and patients with IS (p = 0.0001). PVL was similar between groups. Conclusion IFN-γ has high specificity of prediction of subject remain asymptomatic compared with PVL and lymphoproliferation assay tests. IFN-γ has been shown to be a biomarker of progression to intermediate stage and to HAM. The association of other markers with manifestations associated with HTLV-1 infection that does not meet the HAM criteria should be verified.This publication has 40 references indexed in Scilit:
- Incidence of Human T Cell Lymphotropic Virus Type 1-Associated Myelopathy/Tropical Spastic Paraparesis in a Long-Term Prospective Cohort Study of Initially Asymptomatic Individuals in BrazilAIDS Research and Human Retroviruses, 2013
- Epidemiological Aspects and World Distribution of HTLV-1 InfectionFrontiers in Microbiology, 2012
- Neurologic abnormalities in HTLV-I– and HTLV-II–infected individuals without overt myelopathyNeurology, 2009
- IFN‐γ production in response to Tax 161–233, and frequency of CD4+ Foxp3+ and Lin− HLA‐DRhigh CD123+ cells, discriminate HAM/TSP patients from asymptomatic HTLV‐1‐carriers in a Peruvian populationImmunology, 2009
- Long‐Term Variations in Human T Lymphotropic Virus (HTLV)–I and HTLV‐II Proviral Loads and Association with Clinical DataThe Journal of Infectious Diseases, 2006
- Human T-cell lymphotropic virus type I (HTLV-I) proviral DNA viral load among asymptomatic patients and patients with HTLV-I-associated myelopathy/tropical spastic paraparesisBrazilian Journal of Medical and Biological Research, 2005
- Guia de manejo clínico do paciente com HTLV: aspectos neurológicosArquivos de Neuro-Psiquiatria, 2005
- HTLV-I, BRAIN ABNORMALITIES ON MAGNETIC RESONANCE IMAGING, AND RELATION WITH MULTIPLE SCLEROSISThe Lancet, 1987
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986
- ANTIBODIES TO HUMAN T-LYMPHOTROPIC VIRUS TYPE-I IN PATIENTS WITH TROPICAL SPASTIC PARAPARESISThe Lancet, 1985